Patara Pharma is a San Diego-based, clinical-stage biotechnology company led by chairman and CEO Bill Gerhart focused on developing therapeutics for debilitating allergic and inflammatory diseases in orphan or focused patient populations. Its lead candidate, PA101B, is a proprietary formulation of a GPR35 agonist with anti-allergy and anti-inflammatory properties. PA101B is being evaluated in separate Phase II clinical trials for the treatment of refractory chronic cough and indolent systemic mastocytosis. The company will use proceeds from the financing to evaluate PA101B in multiple indications. Patara also entered into a Loan and Security Agreement with Silicon Valley Bank to borrow up to $7M to support its development programs.

Total raised

$33M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2015